# Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

> **NCT02769832** · PHASE2 · COMPLETED · sponsor: **Muhammad Furqan** · enrollment: 32 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02769832
- **Lead sponsor:** Muhammad Furqan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-29
- **Primary completion:** 2021-09-23
- **Final completion:** 2022-07-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769832, "Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02769832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*